CEO, Jakob Lindberg will present at BIO Europe Spring in Stockholm April 3-6

Encouraging phase II data in multiple myeloma was presented at ASH annual meeting in December 2015, the poster can be downloaded here.

Oncopeptides is planning a pivotal phase III superiority study in late-stage multiple myeloma. The program includes 2 additional phase II studies and 1 additional phase I/II study. For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events